# SG2918 For Advanced Malignant Tumors

> **NCT06167486** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Hangzhou Sumgen Biotech Co., Ltd.** · enrollment: 17 (actual)

## Conditions studied

- Advanced Malignant Tumors

## Interventions

- **DRUG:** SG2918

## Key facts

- **NCT ID:** NCT06167486
- **Lead sponsor:** Hangzhou Sumgen Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-26
- **Primary completion:** 2025-11-11
- **Final completion:** 2026-12-28
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06167486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06167486, "SG2918 For Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06167486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*